The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Cited by (1,105)

Items 301–400 of 1,105

1. Cloud computing for genomic data analysis and collaboration
   Langmead, Ben, Nellore, Abhinav · 2018 · Nature Reviews Genetics
2. The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases
   Drew R. Neavin, Duan Liu, Balmiki Ray, Richard M. Weinshilboum · 2018 · International Journal of Molecular Sciences
3. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
   Biswanath Majumder, Baraneedharan Ulaganathan, Saravanan Thiyagarajan, Padhma Radhakrishnan, Harikrishna Narasimhan, Muthu Dhandapani, Nilesh Brijwani, Dency D. Pinto, Arun Prasath, Basavaraja Shanthappa et al. · 2015 · Nature Communications
4. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance
   Abir Mukherjee, Chun-Yi Chiang, Helen A. Daifotis, Kristin M. Nieman, Johannes Francois Fahrmann, Ricardo R. Lastra, Iris L. Romero, Oliver Fiehn, Ernst R. Lengyel · 2020 · Cancer Research
5. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
   Chun-Shik Shin, Prashant Mishra, Jeramie D. Watrous, Valério Carelli, Marilena D’Aurelio, Mohit Jain, David C. Chan · 2017 · Nature Communications
6. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
   Waltraut Lehmann, Dirk Mossmann, Julia Kleemann, Kerstin Mock, Chris Meisinger, Tilman Brummer, Ricarda Herr, Simone Brabletz, Marc P. Stemmler, Thomas Brabletz · 2016 · Nature Communications
7. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
   Sun, Chong, Hobor, Sebastijan, Bertotti, Andrea, Zecchin, Davide, Huang, Sidong, Galimi, Francesco, Cottino, Francesca, Prahallad, Anirudh, Grernrum, Wipawadee, Tzani, Anna et al. · 2014 · Cell Reports
8. Exploiting replicative stress to treat cancer
   Matthias Dobbelstein, Claus Storgaard Sørensen · 2015 · Nature Reviews Drug Discovery
9. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
   Medico, Enzo, Russo, Mariangela, Picco, Gabriele, Cancelliere, Carlotta, Valtorta, Emanuele, Corti, Giorgio, Buscarino, Michela, Isella, Claudio, Lamba, Simona, Martinoglio, Barbara et al. · 2015 · Nature Communications
10. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
    Abaan, Ogan D., Polley, Eric C., Davis, Sean R., Zhu, Yuelin J., Bilke, Sven, Walker, Robert L., Pineda, Marbin, Gindin, Yevgeniy, Jiang, Yuan, Reinhold, William C. et al. · 2013 · Cancer Research
11. Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker for Ferroptosis Sensitivity
    Kenichi Shimada, Miki Hayano, Nen C. Pagano, Brent R. Stockwell · 2016 · Cell chemical biology
12. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
    Junko Murai, Ying Feng, Guoying Karen Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves G. Pommier · 2016 · Oncotarget
13. Translational genomics and recent advances in oral squamous cell carcinoma
    Annie Wai Yeeng Chai, Kue Peng Lim, Sok Ching Cheong · 2019 · Seminars in Cancer Biology
14. Integrated Omics of Metastatic Colorectal Cancer
    Li, Chen, Sun, Yi-Di, Yu, Guan-Yu, Cui, Jing-Ru, Lou, Zheng, Zhang, Hang, Huang, Ya, Bai, Chen-Guang, Deng, Lu-Lu, Liu, Peng et al. · 2020 · Cancer Cell
15. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
    Joo Sang Lee, Lital N. Adler, Hiren Karathia, Narin Nard Carmel, Shiran Rabinovich, Noam Auslander, Rom Keshet, Noa Stettner, Alon Silberman, Lilach Agemy et al. · 2018 · Cell
16. A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
    Joseph Cursons, Fernando Souza-Fonseca-Guimarães, Momeneh Foroutan, Ashley Anderson, Frédéric Hollande, Soroor Hediyeh-zadeh, Andreas Behren, Nicholas D. Huntington, Melissa J. Davis · 2019 · Cancer Immunology Research
17. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
    Townsend, Elizabeth C., Murakami, Mark A., Christodoulou, Alexandra, Christie, Amanda L., Köster, Johannes, DeSouza, Tiffany A., Morgan, Elizabeth A., Kallgren, Scott P., Liu, Huiyun, Wu, Shuo-Chieh et al. · 2016 · Cancer Cell
18. Modeling precision treatment of breast cancer
    Anneleen Daemen, Obi L. Griffith, Laura M. Heiser, Nicholas J. Wang, Oana M. Enache, Zack Sanborn, Francois Pepin, Steffen Durinck, James E. Korkola, Malachi Griffith et al. · 2013 · Genome biology
19. SIRT6 suppresses pancreatic cancer through control of Lin28b
    Sita Kugel, Carlos Sebastián, Julien Fitamant, K. Ross, S. Saha, E. Jain, A. Gladden, Kshitij S Arora, Y. Kato, M. Rivera et al. · 2016 · Cell
20. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism
    Grassian, Alexandra R., Parker, Seth J., Davidson, Shawn M., Divakaruni, Ajit S., Green, Courtney R., Zhang, Xiamei, Slocum, Kelly L., Pu, Minying, Lin, Fallon, Vickers, Chad et al. · 2014 · Cancer Research
21. Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning
    Arbab, Mandana, Shen, Max W., Mok, Beverly, Wilson, Christopher, Matuszek, Żaneta, Cassa, Christopher A., Liu, David R. · 2020 · Cell
22. Translational value of mouse models in oncology drug development
    Gould, Stephen E, Junttila, Melissa R, de Sauvage, Frederic J · 2015 · Nature Medicine
23. Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation
    Jiajun Zhu, Mirela Berisa, Simon Schwörer, Weige Qin, Justin R. Cross, Craig B. Thompson · 2019 · Cell Metabolism
24. Molecularly targeted cancer therapy: some lessons from the past decade
    Min Huang, Aijun Shen, Jian Ding, Meiyu Geng · 2013 · Trends in Pharmacological Sciences
25. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions
    Min Tang, Qi Xie, Ryan C. Gimple, Zheng Zhong, Trevor Tam, Jing Tian, Reilly L. Kidwell, Qiulian Wu, Briana C. Prager, Zhixin Qiu et al. · 2020 · Cell Research
26. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
    Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase, Naoko Hata Sugi, Yuji Yamamoto, Masao Iwata, Akihiko Tsuruoka · 2013 · Cancer Letters
27. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer
    Chen, Yang, Yang, Sujuan, Tavormina, Jena, Tampe, Desiree, Zeisberg, Michael, Wang, Huamin, Mahadevan, Krishnan K., Wu, Chang-Jiun, Sugimoto, Hikaru, Chang, Chia-Chi et al. · 2022 · Cancer Cell
28. Reproducible pharmacogenomic profiling of cancer cell line panels
    Peter M. Haverty, Eva Lin, Jenille Tan, Yihong Yu, Billy Lam, Steve Lianoglou, Richard M. Neve, Scott E. Martin, Jeff Settleman, Robert L. Yauch et al. · 2016 · Nature
29. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
    Yusuke Takahashi, Genta Sawada, Jyunji Kurashige, Ryutaro Uchi, Tae Matsumura, Ueo H, Yuki Takano, Hidetoshi Eguchi, Tomoya Sudo, Keishi Sugimachi et al. · 2013 · British Journal of Cancer
30. Cancer heterogeneity—a multifaceted view
    F. de Sousa e Melo, L. Vermeulen, E. Fessler, J. Medema · 2013 · EMBO Reports
31. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors
    Gao Zhang, Dennie Tompers Frederick, Lawrence Wen Wu, Zhi Wei, Clemens Krepler, Satish Srinivasan, Young Chan Chae, Xiaowei Xu, Harry Choi, Elaida Dimwamwa et al. · 2016 · Journal of Clinical Investigation
32. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features
    Rémi Buisson, Adam Langenbucher, Danae Bowen, Eugene E. Kwan, Cyril H. Benes, Lee Zou, Michael S. Lawrence · 2019 · Science
33. The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
    Aaron S. Meyer, Miles Aaron Miller, Frank B. Gertler, Douglas A. Lauffenburger · 2013 · Science Signaling
34. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality
    Livnat Jerby‐Arnon, Nadja Pfetzer, Yedael Y. Waldman, Lynn McGarry, Daniel T. James, Emma J. Shanks, Brinton A. Seashore-Ludlow, Adam Weinstock, Tamar Geiger, Paul A. Clemons et al. · 2014 · Cell
35. STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq
    Brian J. Haas, Alexander Dobin, Nicolas Stransky, Bo Li, Xiao Feng Yang, Timothy L. Tickle, Asma Bankapur, Carrie L. Ganote, Thomas G. Doak, Nathalie L.M.M. Pochet et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
36. An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia
    Tanja Andrea Gruber, Amanda Larson Gedman, Jinghui Zhang, Cary Koss, Suresh Marada, Huy Q. Ta, Shann-Ching Chen, Xiaoping Su, Stacey K. Ogden, Jinjun Dang et al. · 2012 · Cancer Cell
37. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia
    Jacob D. Jaffe, Yan Wang, Ho Man Chan, Jinghui Zhang, Robert Huether, Gregory V. Kryukov, Hyo-Eun Carrie Bhang, Jordan E. Taylor, Min Hu, Nathan P. Englund et al. · 2013 · Nature Genetics
38. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
    Adam David Durbin, Mark W. Zimmerman, Neekesh V. Dharia, Brian J. Abraham, Amanda Balboni Iniguez, Nina Weichert‐Leahey, Shuning He, John Michael Krill-Burger, David E. Root, Francisca Vázquez et al. · 2018 · Nature Genetics
39. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
    Heidi E. Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko Tanaka, Cai‐Hong Yun, Xiaohong Zhang, Se‐Hoon Lee, Jeonghee Cho, Lauren Ambrogio et al. · 2012 · Proceedings of the National Academy of Sciences
40. Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
    Nikhil Wagle, Brian C. Grabiner, Eliezer M. Van Allen, Eran Hodis, Susanna Joan Jacobus, Jeffrey G. Supko, Michelle L. Stewart, Toni K. Choueiri, Leena Gandhi, James M. Cleary et al. · 2014 · Cancer Discovery
41. Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences
    Himel Mallick, Eric A. Franzosa, Lauren J. Mclver, Soumya Banerjee, Alexandra Sirota‐Madi, Aleksandar David Kostic, Clary B. Clish, Hera C. Vlamakis, Ramnik J. Xavier, Curtis Huttenhower · 2019 · Nature Communications
42. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
    Felix Dietlein, Lisa Thelen, Hans Christian Reinhardt · 2014 · Trends in Genetics
43. mRMRe: an R package for parallelized mRMR ensemble feature selection
    Nicolas De Jay, Simon Papillon‐Cavanagh, Catharina Olsen, Nehmé El-Hachem, Gianluca Bontempi, Benjamin Haibe‐Kains · 2013 · Bioinformatics
44. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
    Andrew E. Goodspeed, Laura M. Heiser, Joe W. Gray, James C. Costello · 2015 · Molecular Cancer Research
45. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer
    Alexandre F. Aissa, Abul Bashar Mir Md. Khademul Islam, Majd Ariss, Cammille C. Go, Alexandra E. Rader, Ryan D. Conrardy, Alexa M Gajda, Carlota Rubio-Pérez, Klara Valyi‐Nagy, Mary M. Pasquinelli et al. · 2021 · Nature Communications
46. SLFN11 Blocks Stressed Replication Forks Independently of ATR
    Murai, Junko, Tang, Sai-Wen, Leo, Elisabetta, Baechler, Simone A., Redon, Christophe E., Zhang, Hongliang, Al Abo, Muthana, Rajapakse, Vinodh N., Nakamura, Eijiro, Jenkins, Lisa M. Miller et al. · 2018 · Molecular Cell
47. Evaluation of Hybridization Capture Versus Amplicon‐Based Methods for Whole‐Exome Sequencing
    Eric Samorodnitsky, Benjamin M. Jewell, Raffi Hagopian, Jharna Miya, Michele R. Wing, Ezra Lyon, Senthilkumar Damodaran, Darshna Bhatt, Julie W. Reeser, Jharna Datta et al. · 2015 · Human Mutation
48. Codon-specific translation reprogramming promotes resistance to targeted therapy
    Rapino, Francesca, Delaunay, Sylvain, Rambow, Florian, Zhou, Zhaoli, Tharun, Lars, De Tullio, Pascal, Sin, Olga, Shostak, Kateryna, Schmitz, Sebastian, Piepers, Jolanda et al. · 2018 · Nature
49. Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser
    Melissa Cline, Brian Craft, Teresa Swatloski, Mary J. Goldman, Singer Ma, David H. Haussler, Jingchun Zhu · 2013 · Scientific Reports
50. Computational genomics tools for dissecting tumour–immune cell interactions
    Hubert Hackl, Pornpimol Charoentong, Francesca Finotello, Zlatko Trajanoski · 2016 · Nature Reviews Genetics
51. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
    Wong, Gabrielle S., Zhou, Jin, Liu, Jie Bin, Wu, Zhong, Xu, Xinsen, Li, Tianxia, Xu, David, Schumacher, Steven E., Puschhof, Jens, McFarland, James et al. · 2018 · Nature Medicine
52. Cancer transcriptome profiling at the juncture of clinical translation
    Marcin P. Cieslik, Arul M. Chinnaiyan · 2017 · Nature Reviews Genetics
53. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs
    Kevin Hadi, Xiaotong Yao, Julie M. Behr, Aditya S. Deshpande, Charalampos Xanthopoulakis, Huasong Tian, Sarah Kudman, Joel A. Rosiene, Madison Darmofal, Joseph DeRose et al. · 2020 · Cell
54. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer
    Zhao Zhang, Joo‐Hyung Lee, Hang Ruan, Youqiong Ye, Joanna Krakowiak, Qingsong Hu, Yu Xiang, Jing Gong, Bingying Zhou, Li Wang et al. · 2019 · Nature Communications
55. bHLH-PAS proteins in cancer
    Bersten, David C., Sullivan, Adrienne E., Peet, Daniel J., Whitelaw, Murray L. · 2013 · Nature Reviews Cancer
56. DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
    Jinxian Wang, Xuejun Liu, Siyuan Shen, Lei Deng, Hui Liu · 2021 · Briefings in Bioinformatics
57. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response
    Qiao Liu, Zhiqiang Hu, Rui Jiang, Mu Zhou · 2020 · Bioinformatics
58. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
    Pance, Katarina, Gramespacher, Josef A., Byrnes, James R., Salangsang, Fernando, Serrano, Juan-Antonio C., Cotton, Adam D., Steri, Veronica, Wells, James A. · 2023 · Nature Biotechnology
59. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
    Viktoras Frismantas, Maria Pamela Dobay, Anna Maria Rinaldi, Joëlle Tchinda, Samuel Hunter Dunn, Joachim B. Kunz, Paulina Richter‐Pechańska, Blerim Marovca, Orrin Pail, Silvia Jenni et al. · 2017 · Blood
60. DrugComb: an integrative cancer drug combination data portal
    Bulat Zagidullin, Jehad Aldahdooh, Shuyu Zheng, Wenyu Wang, Yinyin Wang, Joseph J Saad, Alina Malyutina, Mohieddin Jafari, Ziaurrehman Tanoli, Alberto Pessia et al. · 2019 · Nucleic Acids Research
61. Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
    Stephen H Safe, Syng‐Ook Lee, Un-Ho Jin · 2013 · Toxicological Sciences
62. PharmacoGx: an R package for analysis of large pharmacogenomic datasets
    Petr Smirnov, Zhaleh Safikhani, Nehmé El-Hachem, Dong Wang, Adrian She, Catharina Olsen, Mark Freeman, Heather Marie Selby, Deena M.A. Gendoo, Patrick Großmann et al. · 2015 · Bioinformatics
63. Deep learning-based approaches for multi-omics data integration and analysis
    Jenna L. Ballard, Zexuan Wang, Wenrui Li, Li Shen, Qi Long · 2024 · BioData Mining
64. Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
    Kha‐Liang Lee, Yung‐Che Kuo, Yuan‐Soon Ho, Yen‐Hua Huang · 2019 · Cancers
65. recount3: summaries and queries for large-scale RNA-seq expression and splicing
    Christopher Wilks, Shijie Zheng, Feng Yong Chen, Rone Charles, Brad Solomon, Jonathan P. Ling, Eddie L. Imada, David Zhang, Lance Joseph, Jeffrey T. Leek et al. · 2021 · Genome biology
66. The cancer genome atlas pan-cancer analysis project
    Mills, Gordon B., Mills Shaw, Kenna R., Shmulevich, Ilya, Joshua M. Stuart, Ellrott, Kyle, Chris Sander, The Cancer Genome Atlas Research Network, Collisson, Eric A., Ozenberger, Brad A., Weinstein, John N. · 2019 · Europe PMC (PubMed Central)
67. Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd
    Zichen Wang, Caroline D. Monteiro, Kathleen M. Jagodnik, Nicolas Fernandez, Gregory W. Gundersen, Andrew D. Rouillard, Sherry L. Jenkins, Axel S. Feldmann, Kevin S. Hu, Michael G. McDermott et al. · 2016 · Nature Communications
68. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
    Peter Kalev, Marc L. Hyer, Stefan Größ, Zenon D. Konteatis, Chi-Chao Chen, Mark Fletcher, Max Lein, Elia Aguado-Fraile, Victoria Elizabeth Frank, Amelia Barnett et al. · 2021 · Cancer Cell
69. Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer
    Hernan Roca, James R. Hernandez, Savannah Weidner, Richard C. McEachin, David E.H. Fuller, Sudha Sud, Taibriana Schumann, John Erby Wilkinson, Alexander Zaslavsky, Hangwen Li et al. · 2013 · PLoS ONE
70. Elucidating Distinct Roles for <i>NF1</i> in Melanomagenesis
    Maertens, Ophélia, Johnson, Bryan, Hollstein, Pablo, Frederick, Dennie T., Cooper, Zachary A., Messiaen, Ludwine, Bronson, Roderick T., McMahon, Martin, Granter, Scott, Flaherty, Keith et al. · 2013 · Cancer Discovery
71. Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies
    Sveen, Anita, Bruun, Jarle, Eide, Peter W., Eilertsen, Ina A., Ramirez, Lorena, Murumägi, Astrid, Arjama, Mariliina, Danielsen, Stine A., Kryeziu, Kushtrim, Elez, Elena et al. · 2018 · Clinical Cancer Research
72. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
    Andreas Schlicker, Garry J. Beran, Christine M. Chresta, Gael McWalter, Alison Pritchard, Susie L. Weston, Sarah K. Runswick, Sara Davenport, Kerry Heathcote, Denis Alférez et al. · 2012 · BMC Medical Genomics
73. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
    Raymond A. Pagliarini, Wenlin Shao, William R. Sellers · 2015 · EMBO Reports
74. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
    Christine F. Brainson, Chunxiao Xu, Pooja T. Desai, Joanne M. Berry, Samuel P. Rowbotham, Yi-Jang Lin, Haikuo Zhang, Víctor E. Márquez, Peter S. Hammerman, Kwok‐Kin Wong et al. · 2015 · Nature
75. Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
    Michael S. Anglesio, Kimberly C. Wiegand, Nataliya Melnyk, Christine Chow, Clara M. Salamanca, Leah Prentice, Janine Senz, Winnie Yang, Monique A. Spillman, Dawn R. Cochrane et al. · 2013 · PLoS ONE
76. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context
    Hua‐Sheng Chiu, Sonal Somvanshi, Ektaben Patel, Ting-Wen Chen, Vivek Singh, Barry Zorman, Sagar L. Patil, Yinghong Pan, Sujash S. Chatterjee, Rory Johnson et al. · 2018 · Cell Reports
77. Big data in basic and translational cancer research
    Jiang, Peng, Sinha, Sanju, Aldape, Kenneth, Hannenhalli, Sridhar, Sahinalp, Cenk, Ruppin, Eytan · 2022 · Nature Reviews Cancer
78. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
    Shixiang Wang, Mingming Jia, Zaoke He, Xuesong Liu · 2018 · Oncogene
79. Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
    Michaël Cerezo, Ramdane Guemiri, Sabine Druillennec, Isabelle Girault, Hélène Malka-Mahieu, Shensi Shen, Delphine Allard, Sylvain Martineau, Caroline Welsch, Sandrine Agoussi et al. · 2018 · Nature Medicine
80. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery
    Stock, Kristin, Estrada, Marta F., Vidic, Suzana, Gjerde, Kjersti, Rudisch, Albin, Santo, Vítor E., Barbier, Michaël, Blom, Sami, Arundkar, Sharath C., Selvam, Irwin et al. · 2016 · Scientific Reports
81. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells
    Angelika Bröer, Farid Rahimi, Stefan Bröer · 2016 · Journal of Biological Chemistry
82. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
    Antje Sucker, Fang Zhao, Natalia Pieper, Christina Heeke, Raffaela Maltaner, Nadine Stadtler, Birgit Real, Nicola Bielefeld, Sebastian Howe, Benjamin Weide et al. · 2017 · Nature Communications
83. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
    Joshua M. Dempster, Clare Pacini, Sasha Pantel, Fiona M. Behan, Thomas Green, John Michael Krill-Burger, Charlotte Beaver, Scott T. Younger, Victor Zhivich, Hanna Najgebauer et al. · 2019 · Nature Communications
84. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
    Gabriel N. Hortobágyi, David J. Chen, Martine J Piccart, Hope S. Rugo, Howard A. Burris, Kathleen I. Pritchard, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu et al. · 2015 · Journal of Clinical Oncology
85. mTORC1 Balances Cellular Amino Acid Supply with Demand for Protein Synthesis through Post-transcriptional Control of ATF4
    Yeonwoo Park, Andrea Reyna‐Neyra, Lucas Philippe, Carson C. Thoreen · 2017 · Cell Reports
86. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells
    Hugh Gannon, Tao Zou, Michael K. Kießling, Galen F. Gao, Diana Cai, Peter S. Choi, Alexandru P. Ivan, Ilana Buchumenski, Ashton C. Berger, Jonathan T. Goldstein et al. · 2018 · Nature Communications
87. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism
    Nora Kory, Gregory A. Wyant, Gyan Prakash, Jelmi uit de Bos, Francesca Bottanelli, Michael E. Pacold, Sze Ham Chan, Caroline A. Lewis, Tim Wang, Heather R. Keys et al. · 2018 · Science
88. RETRACTED: Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma
    Jian-Jun Xie, Yan-Yi Jiang, Yuan Ying Jiang, Chunquan Li, Mei Chee Lim, Ömer An, Anand Mayakonda, Ling‐Wen Ding, Lin Long, Chun Sun et al. · 2018 · Gastroenterology · Retracted
89. Extrusion bioprinting of soft materials: An emerging technique for biological model fabrication
    Tao Jiang, José G. Munguia-López, Salvador Flores-Torres, Jacqueline Kort-Mascort, Joseph Matthew Kinsella · 2019 · Applied Physics Reviews
90. Clustergrammer, a web-based heatmap visualization and analysis tool for high-dimensional biological data
    Nicolas Fernandez, Gregory W. Gundersen, Adeeb H Rahman, Mark L. Grimes, Klarisa Rikova, Peter V. Hornbeck, Avi Ma’ayan · 2017 · Scientific Data
91. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
    Weihua Zhou, Yangyang Yao, Andrew J. Scott, Kari Wilder-Romans, Joseph Dresser, Christian K. Werner, Hanshi Sun, Drew W. Pratt, Peter Sajjakulnukit, Shuang George Zhao et al. · 2020 · Nature Communications
92. A resource for cell line authentication, annotation and quality control
    Yu, Mamie, Selvaraj, Suresh K., Liang-Chu, May M. Y., Aghajani, Sahar, Busse, Matthew, Yuan, Jean, Lee, Genee, Peale, Franklin, Klijn, Christiaan, Bourgon, Richard et al. · 2015 · Nature
93. DNA methylation-calling tools for Oxford Nanopore sequencing: a survey and human epigenome-wide evaluation
    Yang Liu, Wojciech Rosikiewicz, Ziwei Pan, Nathaniel Jillette, Ping Wang, Aziz Taghbalout, Jonathan Foox, Christopher E. Mason, Martin P Carroll, Albert W. Cheng et al. · 2021 · Genome biology
94. Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
    Leroy, Bernard, Girard, Luc, Hollestelle, Antoinette, Minna, John D., Gazdar, Adi F., Soussi, Thierry · 2014 · Human Mutation
95. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
    Robichaux, Jacqulyne P., Elamin, Yasir Y., Vijayan, R.S.K., Nilsson, Monique B., Hu, Lemei, He, Junqin, Zhang, Fahao, Pisegna, Marlese, Poteete, Alissa, Sun, Huiying et al. · 2019 · Cancer Cell
96. GSEA-InContext: identifying novel and common patterns in expression experiments
    Rani K. Powers, Andrew Goodspeed, Harrison Pielke-Lombardo, Aik Choon Tan, James C. Costello · 2018 · Bioinformatics
97. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivo
    Frank P. Vendetti, Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O’Connor, Christopher J. Bakkenist · 2015 · Oncotarget
98. Deep-Resp-Forest: A deep forest model to predict anti-cancer drug response
    Ran Su, Xinyi Liu, Leyi Wei, Quan Zou · 2019 · Methods
99. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
    Xueqian Gong, Jian Du, Stephen H. Parsons, Farhana F. Merzoug, Yue Webster, Philip W. Iversen, Li-Chun Chio, Robert Daniel Van Horn, Xi Lin, Wayne D. Blosser et al. · 2018 · Cancer Discovery
100. Patterns of ribosomal protein expression specify normal and malignant human cells
     Joao C. Guimaraes, Mihaela Zavolan · 2016 · Genome biology